• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.

作者信息

Weber Patrizia, Seyed Jafari S Morteza, Yawalkar Nikhil, Hunger Robert E

机构信息

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

出版信息

J Am Acad Dermatol. 2017 Jun;76(6):1189-1191. doi: 10.1016/j.jaad.2017.02.026.

DOI:10.1016/j.jaad.2017.02.026
PMID:28522043
Abstract
摘要

相似文献

1
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.阿普米拉斯治疗中度至重度化脓性汗腺炎：9例病例系列
J Am Acad Dermatol. 2017 Jun;76(6):1189-1191. doi: 10.1016/j.jaad.2017.02.026.
2
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.阿普米拉斯用于治疗轻度至中度化脓性汗腺炎的前瞻性、开放标签2期研究
J Drugs Dermatol. 2019 Feb 1;18(2):170-176.
3
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.阿普米司特治疗中重度化脓性汗腺炎的随机对照研究结果。
J Am Acad Dermatol. 2019 Jan;80(1):80-88. doi: 10.1016/j.jaad.2018.06.046. Epub 2018 Jul 3.
4
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.阿普米司特治疗化脓性汗腺炎的长期疗效：对初始应答者的2年随访
J Am Acad Dermatol. 2021 Jul;85(1):258-260. doi: 10.1016/j.jaad.2020.08.113. Epub 2020 Sep 3.
5
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.一种药物，两种疾病：阿普米司特治疗多药耐药性化脓性汗腺炎和银屑病一例。
Dermatol Ther. 2019 Nov;32(6):e13089. doi: 10.1111/dth.13089. Epub 2019 Oct 14.
6
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.阿普米司特治疗中重度化脓性汗腺炎：皮损皮肤炎症生物标志物无显著变化。
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):761-765. doi: 10.1111/jdv.15354. Epub 2018 Dec 10.
7
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.阿普司特治疗合并多种疾病的银屑病关节炎相关化脓性汗腺炎：病例报告及文献综述
Medicine (Baltimore). 2020 Jan;99(5):e18991. doi: 10.1097/MD.0000000000018991.
8
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.沙利度胺治疗重度化脓性汗腺炎：一种治疗选择。
Acta Derm Venereol. 2019 Nov 1;99(12):1170-1171. doi: 10.2340/00015555-3268.
9
Lack of efficacy of apremilast in 9 patients with severe alopecia areata.阿普米拉斯对9例重度斑秃患者无效。
J Am Acad Dermatol. 2017 Oct;77(4):773-774. doi: 10.1016/j.jaad.2017.05.034.
10
Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.英夫利昔单抗治疗重度化脓性汗腺炎：7例连续患者的短暂临床疗效
J Am Acad Dermatol. 2007 Apr;56(4):624-8. doi: 10.1016/j.jaad.2006.07.027. Epub 2007 Jan 22.

引用本文的文献

1
Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.阿普司特治疗免疫介导的炎症性皮肤病：一项叙述性综述。
Front Pharmacol. 2025 Aug 21;16:1633426. doi: 10.3389/fphar.2025.1633426. eCollection 2025.
2
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
3
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.
坏疽性脓皮病和化脓性汗腺炎的新治疗方法：综述。
J Dermatol. 2024 Feb;51(2):172-179. doi: 10.1111/1346-8138.17031. Epub 2023 Nov 27.
4
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
5
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
6
Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis.阿达木单抗对化脓性汗腺炎患者疼痛的影响：系统评价与荟萃分析
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022099. doi: 10.5826/dpc.1202a99. eCollection 2022 May.
7
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
8
Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.化脓性汗腺炎：宿主-微生物与免疫发病机制是重要的未来研究方向的基础。
JID Innov. 2021 Jan 12;1(1):100001. doi: 10.1016/j.xjidi.2021.100001. eCollection 2021 Mar.
9
Insights into the Pathogenesis of HS and Therapeutical Approaches.化脓性汗腺炎发病机制及治疗方法的见解。
Biomedicines. 2021 Sep 6;9(9):1168. doi: 10.3390/biomedicines9091168.
10
Refractory erythema annulare centrifugum treated with apremilast.用阿普米拉斯治疗难治性离心性环状红斑。
JAAD Case Rep. 2021 Jul 27;15:100-103. doi: 10.1016/j.jdcr.2021.07.012. eCollection 2021 Sep.